Virtual Workshop: Exploring Opportunities and Feasibility of Trials on Effects of Increasing NAD+ Levels in Older Adults

Date: December 9, 2021 from 10am-5:45pm, ET

Sponsored by: NIA's Division of Geriatrics and Clinical Gerontology

Registration Information

Register for the workshop. 

Materials

• Workshop program
• Workshop objectives

Agenda 

Day 1

10:00am-10:05am: Welcome and Introductions

10:05am-10:15am: Charge to Participants, Evan Hadley, National Institute on Aging, NIH

10:15am-12:20pm:Session 1: Aging and NAD+ Level

• 10:15am-10:45am: Effect of nicotinamide mononucleotide on metabolic health and frailty, David Sinclair, Harvard University
• 10:45am-11:15am: The NAD Metabolome Promotes Resiliency to Conditions of Metabolic Stress and 99% of What You’ve Been Told About Sirtuins and Longevity is Wrong, Charles Brenner, City of Hope National Medical Center, Duarte, California
• 11:15am-11:40am: The NAD World 3.0: the importance of the inter-tissue communication in mammalian aging and longevity control, Shin-Ichiro Imai, Washington University
• 11:40am-12:00pm: NAD supplementation in diseases with DNA repair deficiency, Vilhelm Bohr, National Institute on Aging, NIH
• 12:00pm-12:20pm: Novel neuroimaging approaches to measure in vivo NAD+ and NADH, Fei Du, McLean Hospital

12:20pm-12:50pm: Break 

12:50pm-2:10pm: Session II: Therapeutic Targets for Boosting NAD+ in Aging

• 12:50pm-1:10pm: NAD precursors cycle between the host and gut microbiome, Joseph Baur, University of Pennsylvania
• 1:10pm-1:30pm: CD38 as a therapeutic target, Eduardo Chini, Mayo Clinic
• 1:30pm-1:50pm: Normalization of NAD+ redox balance as a therapy for heart failure, Rong Tian, University of Washington
• 1:50pm-2:10pm: Mitochondrial nutrient sensing as a target for therapeutic intervention, Michael Zemel, NuSirt Biopharma & Kinexum

2:10pm-2:40pm: Break

2:40pm-3:40pm: Session III: Clinical Experience Targeting NAD Therapeutically

• 2:40pm-3:00pm: Clinical evidence for targeting NAD therapeutically. Review of completed clinical trials for NAD+ boosting, Eric Verdin, Buck Institute for Research on Aging
• 3:00pm-3:20pm: Safety and metabolism of long-term administration of nicotinamide riboside, Andrew Shao, ChromaDex Inc.
• 3:20pm-3:40pm: Oral Supplementation of NAD+ Precursors for Promoting Healthy Cardiovascular Aging, Douglas Seals, University of Colorado

3:40pm-4:00pm: Break

4:00pm-5:45pm: Session III: Clinical Experience Targeting NAD Therapeutically (Continued)

• 4:00pm-4:20pm: NAD+ boosting compounds to improve memory and cerebrovascular function, Christopher Martens, University of Delaware 
• 4:20pm-4:40pm: Sirtuin-NAD activators in COVID-19 infection, Shalender Bhasin, Brigham and Women's Hospital, Harvard University 
• 4:40pm-5:00pm: Effect of nicotinamide mononucleotide (NMN) on cardiometabolic function, Samuel Klein, Washington University
• 5:00pm-5:45pm: Group Discussion: What should we try to treat or prevent and who is the target population(s)? What types of trials are feasible and needed?, Moderator: Shalender Bhasin, Brigham and Women's Hospital, Harvard University 

Contact Information

• Meeting Program or Agenda: Irina Sazonova, NIA
• Meeting Registration:  Slavica Acott, Sigma Health Consulting, LLC
• IT Support:Gozde Sandal, Sigma Health Consulting, LLC